MedTrace Logo

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

NCT07147101 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-04-21

No results posted yet for this study

Summary

To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.

Conditions

  • Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Sintilimab

Sintilimab will be administered by IV, 200 mg every 3 weeks

DRUG

Bevacizumab Biosimilar

Bevacizumab biosimilar will be administered by IV, 15 mg/kg every 3 weeks.

DRUG

Camrelizumab

Camrelizumab will be administered by IV, 200 mg every 2 weeks.

DRUG

Rivoceranib

Rivoceranib will be administered by oral 250 mg once daily.

DRUG

Nivolumab

Nivolumab will be administered by IV, 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks

DRUG

Ipilimumab

Ipilimumab will be administered by IV, 3mg/kg every 3 weeks for up to four doses.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2028-09-01
Completion
2028-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07147101 on ClinicalTrials.gov